Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof
AssigneeAmgen Inc.
InventorsNeeraj Jagdish Agrawal, Kevin Graham, Agnes Eva Hamburger, Christopher Mohr, Derek E. Piper, Kenneth William Walker, Zhulun Wang, Cen Xu
Life of this patent
Estimating the term…
Abstract
The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
Claims24
An isolated polynucleotide that encodes a heavy chain polypeptide and a light chain polypeptide of a monoclonal antibody that specifically binds to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1), wherein:
- (i) the heavy chain polypeptide comprises a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein CDRH1 comprises the sequence of SEQ ID NO:
- 88, CDRH2 comprises the sequence of SEQ ID NO:
- 108, and CDRH3 comprises the sequence of SEQ ID NO:
- 171;
- and
- (ii) the light chain polypeptide comprises a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein CDRL1 comprises the sequence of SEQ ID NO:
- 7, CDRL2 comprises the sequence of SEQ ID NO:
- 26, and CDRL3 comprises the sequence of SEQ ID NO:
- 36.
A set of isolated polynucleotides encoding a heavy chain polypeptide and a light chain polypeptide of a monoclonal antibody that specifically binds to human PAC1, comprising:
- (i) a first polynucleotide encoding the heavy chain polypeptide, which comprises a heavy chain variable region comprising a CDRH1 comprising the sequence of SEQ ID NO:
- 88, a CDRH2 comprising the sequence of SEQ ID NO:
- 108, and a CDRH3 comprising the sequence of SEQ ID NO:
- 171;
- and
- (ii) a second polynucleotide encoding the light chain polypeptide, which comprises a light chain variable region comprising a CDRL1 comprising the sequence of SEQ ID NO:
- 7, a CDRL2 comprising the sequence of SEQ ID NO:
- 26, and a CDRL3 comprising the sequence of SEQ ID NO:
- 36.
Dependencies are inferred from the claim text.